In the last three months, 12 analysts have published ratings on Bristol-Myers Squibb (NYSE:BMY), offering a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 1 | 7 | 1 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 1 | 1 | 2 | 0 | 0 |
| 2M Ago | 2 | 0 | 3 | 1 | 0 |
| 3M Ago | 0 | 0 | 1 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $55.67, a high estimate of $65.00, and a low estimate of $37.00. This current average has increased by 14.24% from the previous average price target of $48.73.
Exploring Analyst Ratings: An In-Depth Overview
In examining recent analyst actions, we gain insights into how financial experts perceive Bristol-Myers Squibb. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Andrew Baum | Citigroup | Raises | Neutral | $60.00 | $53.00 |
| David Risinger | Leerink Partners | Raises | Outperform | $60.00 | $54.00 |
| Louise Chen | Scotiabank | Raises | Sector Perform | $60.00 | $53.00 |
| Andrew Baum | Citigroup | Raises | Neutral | $53.00 | $45.00 |
| Michael Yee | UBS | Raises | Buy | $65.00 | $46.00 |
| Tim Anderson | B of A Securities | Raises | Buy | $61.00 | $52.00 |
| Terence Flynn | Morgan Stanley | Raises | Underweight | $37.00 | $36.00 |
| Seamus Fernandez | Guggenheim | Announces | Buy | $62.00 | - |
| Mohit Bansal | Wells Fargo | Raises | Equal-Weight | $55.00 | $53.00 |
| Louise Chen | Scotiabank | Raises | Sector Perform | $53.00 | $45.00 |
| Asad Haider | Goldman Sachs | Raises | Neutral | $57.00 | $51.00 |
| Andrew Baum | Citigroup | Lowers | Neutral | $45.00 | $48.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Bristol-Myers Squibb. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Bristol-Myers Squibb compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Bristol-Myers Squibb's stock. This comparison reveals trends in analysts' expectations over time.
For valuable insights into Bristol-Myers Squibb's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Bristol-Myers Squibb analyst ratings.
All You Need to Know About Bristol-Myers Squibb
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Breaking Down Bristol-Myers Squibb's Financial Performance
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3M period, Bristol-Myers Squibb showcased positive performance, achieving a revenue growth rate of 2.77% as of 30 September, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 18.01%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Bristol-Myers Squibb's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 12.23%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Bristol-Myers Squibb's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.3%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 2.75, Bristol-Myers Squibb faces challenges in effectively managing its debt levels, indicating potential financial strain.
Analyst Ratings: Simplified
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
